GSK Says No To Early Stage Deal-Making, Citing High Likelihood Of Failure
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline's in-licensing efforts will focus on late-stage compounds due to the high risk of earlier stage deals, CEO J.P. Garnier said Feb. 8